OS-01 (Peptide 14): Research & Studies
Scientific evidence, clinical trials, and research findings
📌TL;DR
- •4 clinical studies cited
- •Overall evidence level: low
- •7 research gaps identified
Research Studies
Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models
Zonari A, Brace LE, Al-Kateb K, et al. (2023) • npj Aging
Foundational study identifying Peptide 14 through two-step phenotypic screening of >900 candidates. Tested in four senescence models. Showed PP2A modulation as mechanism and reduced DNA methylation age in ex vivo human skin.
Key Findings
- Reduced senescence in HGPS, UV, chronological aging, and etoposide models
- PP2A modulation identified as primary mechanism via PPP2R1A regulatory subunit
- Decreased CDKN2A (p16INK4a) in both dermal and epidermal layers
- Reduced DNA methylation age in ex vivo skin
- Outperformed retinol in epidermal thickness and skin health markers
- Reduced SASP (senescence-associated secretory phenotype) markers
Limitations: All authors affiliated with OneSkin; proprietary peptide prevents independent replication; ex vivo models do not fully recapitulate in vivo aging
Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation
Zonari A, Brace LE, Harder NHO, et al. (2024) • Journal of Cosmetic Dermatology
12-week split-face, double-blinded study. Participants applied OS-01 formulation on one side of face and identical vehicle control on the other. Assessed barrier function, hydration, and aging markers.
Key Findings
- Significant improvement in skin barrier function (reduced TEWL)
- Improvements detected by instrumental measurement and clinical grading
- Split-face design eliminated inter-individual variability
Limitations: Small sample size (n=22); industry-sponsored; cosmetic product context; short-term (12 weeks)
OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12-Week Clinical Trial
Zonari A, Brace LE, Harder NHO, et al. (2025) • Journal of Cosmetic Dermatology
Largest OS-01 trial to date. Randomized, double-blinded, 12-week study in women aged 60-90. Compared OS-01 body lotion to commercial moisturizer. Measured skin parameters, circulating cytokines, and GlycanAge.
Key Findings
- 70% of OS-01 group noticed skin improvement vs 42% control
- 41.49% improvement in transepidermal water loss
- Significant decrease in circulating IL-8
- GlycanAge suggested slowing of systemic biological aging
- TNF-alpha and IFN-gamma increased in control but stable in OS-01 group
Limitations: Pilot study; industry-sponsored; control was commercial moisturizer not identical vehicle; GlycanAge not fully validated as biological age measure; systemic effects from topical application are mechanistically unclear
Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging
Zonari A, Brace LE, Harder NHO, et al. (2025) • International Journal of Cosmetic Science
12-week study evaluating OS-01 EYE formulation for periorbital aging. Participants applied product twice daily. Assessed hydration, barrier function, firmness, elasticity, fine lines, and dark circles.
Key Findings
- TEWL decreased by 17.33% from baseline
- Skin hydration increased by 32.49%
- Skin firmness improved by 10.19%
- Elasticity increased by 25.58%
- Improvements in fine lines, wrinkles, and dark circles by expert grading
Limitations: Small sample size (n=22); no vehicle control group; industry-sponsored; single-arm design limits causal inference
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles · 30+ comparisons · 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 200+ community reports
View community protocolsExplore research gaps across all peptides → | View clinical trial pipeline →
🔍Research Gaps & Future Directions
- •No independent (non-OneSkin affiliated) studies have been conducted
- •Peptide sequence is proprietary, preventing independent synthesis and replication
- •No long-term safety or efficacy data beyond 12 weeks
- •Systemic effects from topical application lack mechanistic explanation
- •No head-to-head comparisons with other anti-aging peptides or senolytics
- •No studies in male participants or diverse age groups
- •Clinical trials published in cosmetic journals rather than aging or pharmacology journals
Research Overview#
OS-01 (Peptide 14) has been evaluated in one preclinical study and three clinical trials, all published between 2023 and 2025. The entire body of evidence has been generated by OneSkin researchers or close affiliates, which is an important consideration when evaluating the strength of the evidence.
The research trajectory has moved from in vitro and ex vivo validation (2023) to progressively larger clinical trials, culminating in a 60-participant RCT (2025). While the direction of results is consistently positive, the evidence base remains limited by industry sponsorship, small sample sizes, and the proprietary nature of the peptide.
Key Studies#
Preclinical Foundation (2023)#
The foundational study published in npj Aging (PMID: 37217561) identified Peptide 14 through a two-step phenotypic screening of over 900 peptide candidates. The screening assessed ability to reduce senescence markers in human dermal fibroblasts.
Key preclinical findings include:
- Efficacy across four distinct senescence induction models (HGPS, UV radiation, chronological aging, and etoposide)
- PP2A modulation as the primary mechanism, with single-cell transcriptomics showing enhanced DNA repair and cell cycle regulation
- Reduction of CDKN2A (p16INK4a) expression in both epidermal and dermal layers of ex vivo human skin
- Decreased DNA methylation age in treated ex vivo samples
- Superior performance compared to retinol on several skin health markers
Clinical Evidence (2024-2025)#
Three clinical trials have evaluated OS-01 in topical formulations:
Split-Face RCT (2024, n=22): The first human study used a split-face design where participants applied OS-01 formulation on one half of the face and identical vehicle on the other for 12 weeks. This well-controlled design showed significant improvement in skin barrier function measured by transepidermal water loss (TEWL).
Body Lotion RCT (2025, n=60): The largest trial randomized women aged 60-90 to OS-01 body lotion or a commercial moisturizer control for 12 weeks. Results showed 70% reported skin improvement in the OS-01 group versus 42% in controls, with measurable improvements in TEWL (41.49%), decreased circulating IL-8, and slowed biological aging by GlycanAge assessment.
Periorbital Study (2025, n=22): A single-arm study of OS-01 EYE formulation showed improvements in hydration (32.49%), elasticity (25.58%), TEWL (17.33% reduction), and firmness (10.19%) after 12 weeks of twice-daily application.
Evidence Quality Assessment#
The evidence for OS-01 is rated as low based on the following considerations:
Strengths:
- Published in peer-reviewed journals
- Includes double-blinded, randomized controlled trial designs
- Mechanistic work provides plausible biological rationale
- Consistent positive direction across multiple studies
Limitations:
- All studies conducted by OneSkin researchers or affiliates
- No independent replication from external groups
- Proprietary peptide sequence prevents independent synthesis
- Small sample sizes (22-60 participants)
- Published in cosmetic rather than pharmacological journals
- 12-week maximum follow-up
- No male participants in clinical trials
- Control group in largest trial used different commercial product, not identical vehicle
- Systemic effects from topical application lack mechanistic clarity
Research Gaps#
The following gaps remain in the OS-01 evidence base:
- Independent replication -- no studies from researchers without OneSkin affiliation
- Long-term data -- no evidence beyond 12 weeks of treatment
- Mechanistic clarity -- how topical application produces systemic cytokine and biological age changes is unexplained
- Diverse populations -- studies limited to women, predominantly older adults
- Comparative studies -- no head-to-head trials against other anti-aging interventions
- Dose-response -- optimal peptide concentration not systematically studied
- Discontinuation effects -- unclear whether benefits persist after stopping treatment
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.